Shots:
- The EMA has granted ODD to rilzabrutinib for the treatment of IgG4-related disease (IgG4-RD)
- Rilzabrutinib (PO) is being evaluated in a P-II trial for IgG4-RD with glucocorticoids vs glucocorticoids alone, showing reduced flares, improved disease markers, & steroid sparing over 52 weeks; data presented at EULAR 2025
- Rilzabrutinib, a reversible covalent BTK inhibitor, is under the review in the US, EU & China for immune thrombocytopenia (ITP), with the US FDA’s target action date of Aug 29, 2025
Ref: Sanofi | Image: Sanofi | Press Release
Related News:- Sanofi Enters a ~$395M Asset Purchase Agreement with Visirna Therapeutics (Arrowhead) for Plozasiran in Greater China
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
